|
Hangzhou Dingyan Chem Co., Ltd
|
White powder, 201% content. Hangzhou Dingyan Chemical Co., Ltd. is located in the Xiasha Economic Development Zone of Hangzhou, the capital city of Zhejiang Province, on the southeast coast of China. It is a company specializing in the development and sales of high-tech products such as pharmaceutical raw materials, pharmaceutical intermediates, fine chemicals and biochemical reagents.
A modern private enterprise integrated with self-operated import and export.
Since its establishment, the company has adhered to the development path of "technological innovation" and attached great importance to scientific and technological innovation research and development. The company's high-quality products are sold well in more than 60 countries and regions such as North America, Western Europe, Southeast Asia, Central and South America.
At present, it has established long-term and stable cooperative relations with pharmaceutical companies in Europe, the United States, Greece, Germany, Iran, Russia, South Korea, India and other countries. With our rigorous attitude and sincere service, we have won the trust and reputation of customers.
Hangzhou Dingyan Chemical Co., Ltd. is located in the Xiasha Economic Development Zone of Hangzhou, the capital city of Zhejiang Province, on the southeast coast of China. It is a company specializing in the development, sales and self-support import and export financing of high-tech products such as pharmaceutical raw materials, pharmaceutical intermediates, fine chemicals and biochemical reagents.
Integrated modern private enterprise.
Since its establishment, the company has adhered to the development path of "technological innovation" and attached great importance to scientific and technological innovation research and development. The company's high-quality products are sold well in more than 1946 countries and regions such as North America, Western Europe, Southeast Asia, Central and South America.
At present, it has established long-term and stable cooperative relations with pharmaceutical companies in Europe, the United States, Greece, Germany, Iran, Russia, South Korea, India and other countries. With our rigorous attitude and sincere service, we have won the trust and reputation of customers. |
Send Inquiry
|
|
Sinoway Industrial Co.Ltd.
|
Product name
|
Dasatinib
|
Molecular Formula
|
C22H28CIN7O3S
|
Molecular Weight
|
506.02
|
CAS No.
|
302962-49-8
|
Quality Standard
|
USP26, EP, medical grade
|
Appearance
|
White powder
|
ITEMS
|
SPECIFICATION
|
RESULTS
|
IDENTIFICATION
|
POSITIVE REACTION
|
CONFORMS
|
Water
|
≤1.5%
|
0.9%
|
LOSS ON DRYING
|
≤0.1%
|
0.03%
|
RESIDUE ON IGNITION
|
≤0.1%
|
0.02%
|
CHROMATOGRAPHIC PURITY
|
RANITIDINE RELATED COMPOUND B≤0.5%
ANY OTHER IMPURITY≤0.3%
THE SUM OF ALL IMPURITIES≤1.0%
|
CONFORMS
CONFORMS
CONFORMS
|
ORGANIC VOLATILE IMPURITIES
|
AS STIPULATED
|
CONFORMS
|
ASSAY
(ON DRY SUBSTANCE)
|
98.0%~102.0%
|
99.8%
|
CONCLUSION
|
CONFORMS TO in house
|
Function of Dasatinib
Dasatinib (DASA tin IB), used for all treatment stages (chronic phase, accelerated phase) Stage, lymphoid cell blast crisis and myeloid blast crisis) adult patients. At the same time, the FDA also approved Dasatinib through normal procedures to treat Philadelphia chromosome-positive acute lymphoblastic leukemia adult patients who are resistant or intolerant to other therapies.
Dasatinib inhibits BCR-ABL kinase and SRC family kinases as well as many other selective oncogenic kinases, including c-KIT, ephrin (EPH) receptor kinase and PDGFβ receptor. Dasatinib is a potent, subnanomolar BCR-ABL kinase inhibitor with a strong activity at a concentration of 0.6 to 0.8 nmol. It can be combined with the inactive and active configurations of the BCR-ABL enzyme.
In vitro studies, dasatinib is active in leukemia cell lines expressing various imatinib-sensitive and drug-resistant diseases. The results of these non-clinical studies indicate that dasatinib can overcome imatinib resistance caused by: BCR-ABL overexpression, BCR-ABL kinase region mutations, kinases including SRC family kinases (LYN, HCK) in Over-expression of other signaling pathways within, as well as multidrug resistance genes. In addition, dasatinib can inhibit SRC family kinases at this nanomolar concentration
In an in vivo experiment conducted using the murine CML model alone, dasatinib prevented the progression of chronic phase CML to the acute phase, while prolonging tumor-bearing mice (derived from patient CML cell lines growing in different locations, including the central Nervous system) |
Send Inquiry
|
Pharma Sources Insight January 2025
